Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:01 AM ET 8-K
Financial Results Immunic, Inc. IMUX

Immunic Financial Results

Immunic, Inc. reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate, vidofludimus calcium. The company remains on track to report top-line data from its pivotal Phase 3 ENSURE trials in relapsing multiple sclerosis in December 2026, which could support a potential NDA submission.

Term
Q3 2026

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history. We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS.”

Erik Lundgren, Chief Executive Officer of Immunic

“Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive.”

Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic
8:01 AM ET 10-Q
Financial Results TuHURA Biosciences, Inc. HURA

TuHURA Biosciences Q3 2026 Results: Net Loss of $6.41M, Loss Narrows

TuHURA Biosciences reported a net loss of $23.2 million for the nine months ended September 30, 2026, compared to a $23.3 million loss in the prior year. The company significantly increased its total assets to $36.2 million, primarily through the capitalization of $6.9 million in revolving credit facility debt issuance costs and $2.9 million in prepaid R&D expenses.

Key figure
Net loss $6.41M
7:53 AM ET 10-Q
Financial Results Verrica Pharmaceuticals Inc. VRCA

Verrica Pharmaceuticals Q3 2026 Results: Net Loss of $12.4M, Loss Widens

Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.

Key figure
Net loss $12.4M
7:52 AM ET 10-Q
Financial Results Yarrow Bioscience, Inc. YARW

Yarrow Bioscience Q3 2026 Results: Net Loss of $9.72M

Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.

Key figure
Net loss $9.72M
7:50 AM ET 8-K
Financial Results TuHURA Biosciences, Inc. HURA

TuHURA Biosciences Financial Results

TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided updates on its Phase 3 immuno-oncology programs. The company highlighted positive preliminary data from its IFx-2.0 study in Merkel cell carcinoma and received FDA clearance to begin a Phase 1b study for its VISTA-inhibiting antibody, TBS-2025. Management noted that operations remain funded through a $50 million credit facility from its largest shareholder.

Term
Q3 2026

“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months.”

Dr. James Bianco, President and Chief Executive Officer

“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events.”

Dr. James Bianco, President and Chief Executive Officer
7:46 AM ET 8-K
Financial Results Noodles & Co NDLS

Noodles & Financial Results

Noodles & Company reported third quarter 2026 financial results, highlighted by a 9.5% increase in system-wide comparable restaurant sales. Despite a 1.0% decrease in total revenue to $120.9 million, the company significantly narrowed its net loss to $2.1 million and expanded its restaurant contribution margin by 350 basis points to 16.7%.

Term
Q3 2026

“We are very excited that our third quarter performance continued our strong sales momentum and margin expansion, underscoring the sustainability of our growth and the impact of the improvements we have made across the business. System-wide comparable sales grew 9.5%, which was our third consecutive quarter above 9.0% and eighth consecutive quarter of positive comparable sales growth.”

Joe Christina, President and Chief Executive Officer

“We have also reduced debt by more than $9.0 million year to date, further strengthening our financial foundation. Our focus remains on making Noodles & Company a more compelling choice for guests and a more profitable business, with disciplined execution that supports durable, outsized long-term growth.”

Joe Christina, President and Chief Executive Officer
7:45 AM ET 8-K
Financial Results Digi Power X Inc. DGXX

Digi Power X Financial Results

Digi Power X reported Q3 2026 revenue of $12.25 million, an 85% increase over the prior quarter, driven by a 400% surge in AI-related revenue. The company ended the period with $119.6 million in cash and digital currencies and expects to close a $200 million credit facility in Q4 2026 to fund its data center expansion.

Term
Q3 2026
7:37 AM ET 8-K
Financial Results Milestone Pharmaceuticals Inc. MIST

Milestone Pharmaceuticals Financial Results

Milestone Pharmaceuticals reported Q3 2026 financial results, highlighting $1.0 million in net product revenue for CARDAMYST and a 73% increase over the prior quarter. The company announced a 30% reduction in operating expenses, including leadership departures and bringing its sales force in-house, to extend its cash runway into late 2028. This extension is designed to fund operations through the anticipated Phase 3 data readout for etripamil in AFib-RVR expected in 2H 2028.

Term
Q3 2026

“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact. The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”

Joseph Oliveto, President and Chief Executive Officer
7:32 AM ET 10-Q
Financial Results Lument Finance Trust, Inc. LFT

Lument Finance Trust Q3 2026 Results: Net Loss of $12.3M

Lument Finance Trust reported a net loss attributable to common stockholders of $13.5 million for the third quarter of 2026, primarily driven by a $16.5 million provision for credit losses and $5.2 million in real estate owned impairment. Total assets decreased to $1.08 billion from $1.22 billion at year-end 2025, while the company executed a 1-for-10 reverse stock split in September 2026.

Key figure
Net loss $12.3M
7:32 AM ET 8-K
Financial Results Twenty One Capital, Inc. XXI

Twenty One Capital Financial Results

Twenty One Capital reported Q3 2026 financial results, highlighted by a net income of $1.087 billion primarily driven by a $1.093 billion fair-value gain on its Bitcoin holdings. The company ended the quarter with 43,514 Bitcoin and $102.8 million in cash while evaluating new business opportunities across the Bitcoin and energy ecosystems.

Term
Q3 2026

“Our mandate is clear: build a durable, cash-generating business around one of the largest corporate Bitcoin treasuries in the world. A balance sheet is not a business. It is our starting point.”

Raphael Zagury, Chief Executive Officer

“We welcome Bitcoin’s appreciation. But gains from an asset we own are not the same as earnings from businesses we operate. Building the latter is our job.”

Raphael Zagury, Chief Executive Officer
7:31 AM ET 10-Q
Financial Results Twenty One Capital, Inc. XXI

Twenty One Capital Q3 2026 Results: Turns Profitable, Net Income $1.09B

Twenty One Capital, Inc. reported a net income of $1.09 billion for the three months ended September 30, 2026, primarily driven by a $1.09 billion gain from the change in fair value of digital assets. However, for the nine-month period, the company recorded a net loss of $186.5 million as digital asset values fluctuated, while maintaining a significant Bitcoin treasury valued at approximately $3.64 billion.

Key figure
Net income $1.09B
7:31 AM ET 10-Q
Financial Results Milestone Scientific Inc. MLSS

Milestone Scientific Q3 2026 Results: Net Loss of $748K, Loss Narrows

Milestone Scientific reported a net loss of approximately $2.5 million for the nine months ended September 30, 2026, an improvement from a $4.6 million loss in the prior year period. Product sales grew slightly to $7.2 million, while the company significantly reduced operating expenses, particularly in research and development and SG&A.

Key figure
Net loss $748K
7:30 AM ET 8-K
Financial Results XTI Aerospace, Inc. XTIA

XTI Aerospace Financial Results

XTI Aerospace reported Q3 2026 revenue of $35.3 million, a 46.1% increase over proforma Q3 2025 results, driven by strong demand in its Drone Nerds business. The company achieved positive Adjusted EBITDA of $1.6 million and completed a strategic pivot by discontinuing its aircraft business and reducing corporate overhead.

Term
Q3 2026

“Our strategic pivot to focus on our Drone Nerds business is substantially complete. We have discontinued the operation of the XTI aircraft business, rightsized our corporate overhead and are focused on the significant opportunity in the commercial and enterprise drone market.”

Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer

“The growth opportunities we see across our portfolio combined with continued disciplined expense management is expected to lead to the transition to positive ongoing operating cash flows during the fourth quarter of 2026.”

Jeremy Schneiderman, XTI Aerospace’s Interim Chief Executive Officer
7:30 AM ET 10-Q
Financial Results Jade Biosciences, Inc. JBIO ▶ Call

Jade Biosciences Q3 2026 Results: Net Loss of $35.1M, Loss Widens

Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.

Key figure
Net loss $35.1M
7:21 AM ET 8-K
Financial Results Jade Biosciences, Inc. JBIO

Jade Biosciences Financial Results

Jade Biosciences reported third quarter 2026 financial results, highlighting a cash position of $476 million which is expected to fund operations into Q4 2028. The company is preparing to initiate its Phase 3 EVERGREEN trial for JADE101 in IgA nephropathy ahead of schedule in Q4 2026.

Term
Q3 2026

“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile.”

Tom Frohlich, Chief Executive Officer of Jade
7:13 AM ET 10-Q
Financial Results Immunic, Inc. IMUX

Immunic Q3 2026 Results: Net Loss of $42.3M, Loss Widens

Immunic, Inc. reported a net loss of $109.0 million for the nine months ended September 30, 2026, compared to $77.9 million in the prior year, driven by increased research and development and general and administrative expenses. The company significantly strengthened its liquidity, ending the period with $132.0 million in cash following a $187.3 million private placement in February 2026.

Key figure
Net loss $42.3M
7:11 AM ET 10-Q
Financial Results Tvardi Therapeutics, Inc. TVRD

Tvardi Therapeutics Q3 2026 Results: Net Loss of $6.12M, Loss Widens

Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.

Key figure
Net loss $6.12M
7:06 AM ET 8-K
Financial Results Tvardi Therapeutics, Inc. TVRD

Tvardi Therapeutics Financial Results

Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.

Term
Q3 2026

“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi
7:05 AM ET 10-Q
Financial Results Fathom Holdings Inc. FTHM

Fathom Holdings Q3 2026 Results: Net Loss of $21.8M, Loss Widens

Fathom Holdings Inc. reported a significant decline in revenue to $88.6 million for Q3 2026 compared to $115.3 million in the prior year, primarily driven by a $12.1 million impairment charge. The company's net loss widened to $21.8 million for the quarter, and total shareholders' equity decreased from $37.4 million at year-end 2025 to $1.8 million as of September 30, 2026.

Key figure
Net loss $21.8M
7:02 AM ET 10-Q
Financial Results QXO, Inc. QXO

QXO Q3 2026 Results: Net Loss of $123M, Loss Narrows

QXO, Inc. reported a significant expansion in net sales to $4.9 billion for the third quarter of 2026, driven by major acquisitions including Beacon Roofing Supply and TopBuild Corp. Despite the revenue growth, the company recorded a net loss for the nine months ended September 30, 2026, as it integrated these large-scale operations and managed increased interest expenses from acquisition-related debt.

Key figure
Net loss $123M
7:01 AM ET 10-Q
Financial Results SBC Medical Group Holdings Inc SBC

SBC Medical Group Holdings Q3 2026 Results: Net Income $15.7M, Up 22.4% YoY

SBC Medical Group Holdings reported total revenues of $150.8 million for the nine months ended September 30, 2026, a 12.5% increase year-over-year. Net income for the same period rose to $38.9 million, driven by strong performance in related party revenues and improved operational efficiency.

Key figure
Net income $15.7M · +22.4% YoY
7:01 AM ET 8-K
Financial Results Powercompute, Inc. PWCM

Powercompute Financial Results

PowerCompute reported Q3 2026 financial results, achieving net income of $0.4 million compared to a loss in the prior year, driven by fair value gains as Bitcoin prices rose 43%. The company significantly improved its balance sheet by reducing secured debt by 94% and announced the purchase of 600 new S21++ miners to increase hashrate by 10%.

Term
Q3 2026
6:56 AM ET 10-Q
Financial Results Contango Silver & Gold Inc. CTGO

Contango Silver & Gold Q3 2026 Results: Net Loss of $23M, Loss Widens

Contango Silver & Gold Inc. reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $12.0 million loss in the prior year, driven by increased exploration and general administrative expenses. Total assets grew significantly to $492.8 million following the Dolly Varden acquisition, which added substantial mineral property and equipment value.

Key figure
Net loss $23M
6:50 AM ET 8-K
Financial Results SBC Medical Group Holdings Inc SBC

SBC Medical Group Holdings Financial Results

SBC Medical Group reported third quarter 2026 revenue of $59 million, a 35% increase year-over-year, driven by service fee revisions and clinic network expansion. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA grew 66% to $28 million. The company's supported clinic network expanded to 293 locations, representing a year-over-year increase of 36 locations.

Term
Q3 2026

“The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA margin of 47%.”

Yoshiyuki Aikawa, Chairman and CEO

“Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently.”

Yoshiyuki Aikawa, Chairman and CEO
6:50 AM ET 10-Q
Financial Results Milestone Pharmaceuticals Inc. MIST

Milestone Pharmaceuticals Q3 2026 Results: Net Loss of $25.8M, Loss Widens

Milestone Pharmaceuticals reported a significant increase in cash and cash equivalents to $144.5 million as of September 30, 2026, following the recognition of an $82.8 million royalty financing obligation. The company's accumulated deficit grew to $511.1 million, reflecting ongoing development and commercialization preparations for CARDAMYST (etripamil) nasal spray.

Key figure
Net loss $25.8M
6:26 AM ET 10-Q
Financial Results Regional Health Properties, Inc RHEP

Regional Health Properties Q3 2026 Results: Net Loss of $879K

Regional Health Properties reported a net loss of $2.9 million for the nine months ended September 30, 2026, compared to a net income of $0.7 million in the prior year period. While total revenues grew significantly to $70.6 million due to increased patient care and pharmacy revenues, the company faced higher operating expenses and an impairment loss on assets held for sale.

Key figure
Net loss $879K
6:21 AM ET 10-Q
Financial Results Blue Biofuels, Inc. BIOF

Blue Biofuels Q3 2026 Results: Net Loss of $1.39M, Loss Widens

Blue Biofuels, Inc. reported a net loss of $2,799,864 for the nine months ended September 30, 2026, compared to a loss of $1,587,132 in the prior year period. The company remains in the development stage with zero revenue, while operating expenses increased due to higher research and development costs and stock-based compensation.

Key figure
Net loss $1.39M
6:20 AM ET 10-Q
Financial Results First Choice Healthcare Solutions, Inc. FCHS

First Choice Healthcare Solutions Q3 2026 Results: Net Loss of $10.7M, Loss Widens

First Choice Healthcare Solutions reported a significant net loss of $19.1 million for the nine months ended September 30, 2026, primarily driven by $17.4 million in interest expense. The company is currently pivoting its strategy toward a network of nurse practitioner-driven primary care clinics despite having zero revenue in the current period.

Key figure
Net loss $10.7M
6:07 AM ET 10-Q
Financial Results OpenWorld, Inc. OPNW ▶ Call

OpenWorld Q3 2026 Results: Net Loss of $10.2M

OpenWorld, Inc. reported a significant net loss of $16.1 million for the nine months ended September 30, 2026, compared to a net income of $1.0 million in the prior year, primarily driven by a decrease in total revenues and a sharp increase in general and administrative expenses. The period was marked by a reverse acquisition of VerifyMe, Inc. and substantial non-cash stock-based compensation and professional fees totaling over $12 million.

Key figure
Net loss $10.2M
6:06 AM ET 10-Q
Financial Results Hyperion Defi, Inc. HYPD

Hyperion Defi Q3 2026 Results: Net Income $39.6M, Up 497.5% YoY

Hyperion DeFi, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $79.4 million compared to a net loss of $5.5 million in the prior year, primarily driven by $93.6 million in realized and unrealized gains on digital assets. Total assets grew to $146.3 million from $51.8 million at year-end 2025, reflecting substantial appreciation in the company's digital asset holdings.

Key figure
Net income $39.6M · +497.5% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.